CN106983723B - 奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用 - Google Patents
奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN106983723B CN106983723B CN201710316607.4A CN201710316607A CN106983723B CN 106983723 B CN106983723 B CN 106983723B CN 201710316607 A CN201710316607 A CN 201710316607A CN 106983723 B CN106983723 B CN 106983723B
- Authority
- CN
- China
- Prior art keywords
- orlistat
- liposome
- drug
- phosphatide
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001243 orlistat Drugs 0.000 title claims abstract description 95
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims abstract description 93
- 239000002502 liposome Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 18
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 14
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 14
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 14
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 12
- -1 phosphatide Chemical compound 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 235000019441 ethanol Nutrition 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 13
- 238000005538 encapsulation Methods 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000748159 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 35 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102100040048 Ubiquitin carboxyl-terminal hydrolase 35 Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical class CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
L1 | L2 | L3 | L4 | L5 | L6 | L7 | |
粒径(nm) | 98 | 101 | 105 | 157 | 163 | 142 | 151 |
包封率(%) | 91 | 87 | 89 | 57 | 63 | 64 | 51 |
T/d | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
包封率(%)L1 | 91 | 91 | 91 | 90 | 90 | 89 | 89 | 89 |
包封率(%)L2 | 87 | 87 | 86 | 86 | 86 | 86 | 86 | 85 |
包封率(%)L3 | 89 | 89 | 89 | 88 | 88 | 88 | 87 | 87 |
包封率(%)L5 | 63 | 63 | 60 | 54 | 46 | 42 | 30 | 21 |
包封率(%)L6 | 64 | 63 | 52 | 43 | 37 | 32 | 28 | 21 |
样品 | A549 | MCF7 | SH-SY5Y |
DOX | 0.70 | 0.51 | 0.83 |
奥利司他药物组 | 13.51 | 7.571 | 7.102 |
奥利司他脂质体药物组 | 5.378 | 3.516 | 3.15 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710316607.4A CN106983723B (zh) | 2017-05-08 | 2017-05-08 | 奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710316607.4A CN106983723B (zh) | 2017-05-08 | 2017-05-08 | 奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106983723A CN106983723A (zh) | 2017-07-28 |
CN106983723B true CN106983723B (zh) | 2018-08-21 |
Family
ID=59417696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710316607.4A Active CN106983723B (zh) | 2017-05-08 | 2017-05-08 | 奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106983723B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102362863A (zh) * | 2011-11-21 | 2012-02-29 | 山东新时代药业有限公司 | 一种含奥利司他的制剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA022166B1 (ru) * | 2008-01-11 | 2015-11-30 | Ритэ Фамэсутиклс, Инк. | Синтетические тритерпеноиды и их применение в лечении заболеваний |
CN103006601B (zh) * | 2013-01-04 | 2014-07-23 | 青岛大学 | 一种奥利司他片剂及其制备方法 |
-
2017
- 2017-05-08 CN CN201710316607.4A patent/CN106983723B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102362863A (zh) * | 2011-11-21 | 2012-02-29 | 山东新时代药业有限公司 | 一种含奥利司他的制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
奥利司他抗肿瘤的研究进展;陈少波,等;《医学综述》;20150831;第21卷(第15期);第2735-2737页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106983723A (zh) | 2017-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Riva et al. | Improved oral absorption of quercetin from quercetin phytosome®, a new delivery system based on food grade lecithin | |
Yi et al. | Enhanced oral bioavailability and tissue distribution of a new potential anticancer agent, Flammulina velutipes sterols, through liposomal encapsulation | |
CN107412196B (zh) | 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 | |
CN103083239A (zh) | 一种蟾毒灵脂质体及其制备方法和应用 | |
TWI648257B (zh) | 牛樟芝化合物、製備方法及其用途 | |
CN107049944B (zh) | 一种可实现索拉非尼和姜黄素同时给药的聚合物胶束及其制备方法 | |
CN104826122A (zh) | 绿原酸及其衍生物的脂质修饰物及其制备和纯化方法 | |
CN105125592A (zh) | 一种含蟾酥脂溶物的药物及其制备方法 | |
CN101805285B (zh) | 含烟酸姜黄素酯衍生物及其制造方法和用途 | |
CN104826118A (zh) | 绿原酸及其衍生物脂质修饰物的应用 | |
Yu et al. | Gut microbiota-based pharmacokinetic-pharmacodynamic study and molecular mechanism of specnuezhenide in the treatment of colorectal cancer targeting carboxylesterase | |
CN101810577B (zh) | ***的棉酚静脉注射脂肪乳剂 | |
CN106983723B (zh) | 奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用 | |
CN105012234B (zh) | 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途 | |
CN102603847A (zh) | 人参皂苷Rh2脂肪酸酯类化合物制备方法及其医药用途 | |
CN104710433A (zh) | 苯丁酸氮芥衍生物、制备方法及应用 | |
US8227512B2 (en) | Pharmaceutical composition containing daurinol for the prevention and treatment of cancers | |
CN108434101A (zh) | 一种新型的用于抗癌的Tivozanib脂质体、制剂及其制备方法和应用 | |
CN114404362A (zh) | 藤黄酸口服组合物及其在制备肿瘤治疗药物中的应用 | |
CN1329376C (zh) | 一种n(1)-烃基-3′-肟基靛玉红衍生物(i)的制备方法及其医学应用 | |
CN106943605B (zh) | 奥利司他包合物及其制备方法和在抗肿瘤药物中的应用 | |
CN101845052B (zh) | 一类含氮杂环的噻吩并吡啶酮衍生物、其制备方法和用途 | |
EP3153163B1 (en) | Pharmaceutical compound comprising 13 glycerides, formulation and application thereof | |
CN111995629B (zh) | 大根香叶衍生物及其药物组合物和其在医药中的用途 | |
CN109867657B (zh) | 二羟二苯并[b,f][1,5]二氧杂辛环类化合物、制备方法及其药用组合物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Orlistat liposome as well as preparation method and application thereof to anti-tumor drug Effective date of registration: 20200221 Granted publication date: 20180821 Pledgee: Liangjiang branch of Chongqing Rural Commercial Bank Co.,Ltd. Pledgor: Chongqing Zen Pharmaceutical Co.,Ltd. Registration number: Y2020980000293 |
|
CP03 | Change of name, title or address |
Address after: Room 1-6, Jinfeng biomedical industrial park, No. 28, Gaoxin Avenue, Jiulongpo District, Chongqing Patentee after: Zhien Biotechnology Co.,Ltd. Address before: 400039 Jiulongpo District of Chongqing Science Park Road No. 73 of 25 layers Patentee before: Chongqing Zen Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220913 Granted publication date: 20180821 Pledgee: Liangjiang branch of Chongqing Rural Commercial Bank Co.,Ltd. Pledgor: Chongqing Zen Pharmaceutical Co.,Ltd. Registration number: Y2020980000293 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Orlistat liposome and its preparation method and application in antitumor drug Effective date of registration: 20220919 Granted publication date: 20180821 Pledgee: Bank of Hankou Limited by Share Ltd. Chongqing branch Pledgor: Zhien Biotechnology Co.,Ltd. Registration number: Y2022500000071 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230911 Granted publication date: 20180821 Pledgee: Bank of Hankou Limited by Share Ltd. Chongqing branch Pledgor: Zhien Biotechnology Co.,Ltd. Registration number: Y2022500000071 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Olistatam liposomes and their preparation methods, as well as their application in anti-tumor drugs Granted publication date: 20180821 Pledgee: Chongqing Xingnong Financing Guarantee Group Co.,Ltd. Pledgor: Zhien Biotechnology Co.,Ltd. Registration number: Y2024980021783 |